Ingalls & Snyder LLC Sells 1,760 Shares of Elanco Animal Health (NYSE:ELAN)

Ingalls & Snyder LLC lowered its position in Elanco Animal Health (NYSE:ELAN) by 3.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 49,783 shares of the company’s stock after selling 1,760 shares during the period. Ingalls & Snyder LLC’s holdings in Elanco Animal Health were worth $1,466,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Schroder Investment Management Group boosted its holdings in shares of Elanco Animal Health by 175.0% during the 2nd quarter. Schroder Investment Management Group now owns 360,898 shares of the company’s stock valued at $12,198,000 after purchasing an additional 229,658 shares during the last quarter. Prudential Financial Inc. boosted its holdings in shares of Elanco Animal Health by 5.8% during the 2nd quarter. Prudential Financial Inc. now owns 19,240 shares of the company’s stock valued at $650,000 after purchasing an additional 1,050 shares during the last quarter. LPL Financial LLC boosted its holdings in shares of Elanco Animal Health by 7.6% during the 2nd quarter. LPL Financial LLC now owns 31,092 shares of the company’s stock valued at $1,051,000 after purchasing an additional 2,186 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Elanco Animal Health during the 2nd quarter valued at about $3,218,000. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of Elanco Animal Health by 71.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 358,532 shares of the company’s stock valued at $12,118,000 after purchasing an additional 149,473 shares during the last quarter. 98.58% of the stock is owned by institutional investors.

Shares of NYSE:ELAN opened at $30.84 on Thursday. The company has a current ratio of 3.12, a quick ratio of 1.67 and a debt-to-equity ratio of 0.43. Elanco Animal Health has a 12 month low of $25.25 and a 12 month high of $35.46. The company has a 50-day moving average price of $28.40 and a 200 day moving average price of $28.76. The company has a market cap of $10.92 billion, a price-to-earnings ratio of 26.14, a PEG ratio of 2.76 and a beta of 0.74.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. Elanco Animal Health had a net margin of 3.04% and a return on equity of 7.79%. The firm had revenue of $771.30 million during the quarter, compared to the consensus estimate of $765.85 million. During the same quarter last year, the firm earned $0.29 EPS. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. As a group, equities analysts forecast that Elanco Animal Health will post 1.06 EPS for the current year.

In other news, Director John P. Bilbrey acquired 3,766 shares of Elanco Animal Health stock in a transaction that occurred on Friday, November 22nd. The shares were bought at an average cost of $26.58 per share, with a total value of $100,100.28. Following the transaction, the director now directly owns 2,783 shares of the company’s stock, valued at approximately $73,972.14. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.04% of the company’s stock.

ELAN has been the subject of several research reports. ValuEngine raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Bank of America raised shares of Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $34.00 price objective for the company in a report on Thursday, December 19th. TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Tuesday, December 24th. Cleveland Research reissued a “hold” rating on shares of Elanco Animal Health in a report on Thursday, September 26th. Finally, Raymond James initiated coverage on shares of Elanco Animal Health in a report on Thursday, January 9th. They issued a “market perform” rating for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the stock. Elanco Animal Health presently has an average rating of “Hold” and an average target price of $33.24.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Featured Article: Current Ratio

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.